



## Transformative Opportunities in Immune Health & Nutrition

June 2021




## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:

- The Company's ability to raise the funds we need to continue our operations;
- The Company's goal to begin to generate revenues and become profitable;
- Regulation of our products;
- Market acceptance of our products and derivatives thereof;
- The results of current and future testing of our products;
- The anticipated performance and benefits of our product;
- The Company's ability to expand its intellectual property;
- The Company's ability to enter into strategic partnerships;
- The Company's ability to generate licensing fees; and
- The Company's financial condition or results of operations

In some cases, you can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "expects", "plans", "anticipates", "believes", "estimates", "projects", "predicts", "potential" and similar expressions intended to identify forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this presentation to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.

THE INFORMATION IN THIS PRESENTATION IS PROVIDED TO YOU SOLELY FOR INFORMATIONAL PURPOSES AND IS NOT AN OFFER TO BUY OR SELL, A SOLICITATION OF AN OFFER TO BUY OR SELL, ANY SECURITY OR INSTRUMENT OF THE COMPANY, OR TO PARTICIPATE IN ANY INVESTMENT ACTIVITY OR TRADING STRATEGY.



**ZIVO Bioscience, Inc.**  
**A new path to optimal health**

We are creating novel  
drug candidates, food  
additives and functional  
ingredients designed to  
boost immune health in  
humans and animals



# Company Overview

ZIVO BIOSCIENCE, INC. – NASDAQ: ZIVO; ZIVOW

Addressing billion-dollar global animal health issues. Global food supply. Human immune health.  
Not just science, but IMPACT. The promise of global solutions for global problems.

## Biotech/Pharma

Immune modulators to displace antibiotics in global food supply, improve animal health

Patents filed. Tested. Ready to license

Human Immune application in development

## Agtech/Nutrition

Algae biomass as the newest superfood, skin health product, functional ingredient

Patents filed. Tested. Market-ready

Outsourcing production globally



Biotech



Agtech




# Investment Highlights

Potential revenue from multiple income streams. Out-license IP and sell bioproducts. Billion-dollar Biotech & Agtech market verticals span the globe. Small company. Big science.




## EXPERIENCED MANAGEMENT

85+ years of combined  
experience in Life Sciences,  
Therapeutics and Ag Sciences




## INTELLECTUAL PROPERTY

9 patents, 34 patents pending  
plus trademarks & trade secrets  
in Agtech/Biotech IP portfolio



## ADVANCED AGTECH PLATFORM

Innovative products,  
sustainable cultivation  
processes, global footprint



## EXPANDING BIOTECH PIPELINE

Novel immune and anti-  
inflammatory candidates in  
advanced development

Biotech is capable of delivering significant valuation multiples. Agtech is capable of driving near-term revenue.





# What do all these global health issues have in common?



Drug-resistant pathogens  
**Autoimmune Disorders**  
Sepsis/Toxic Shock  
**Poultry Coccidiosis**  
Antibiotic residues in dairy products  
*e.Coli contamination* Antibiotic-laced meat  
Bovine Mastitis  
Type 1 Diabetes **Arthritis**  
Multiple Sclerosis Necrotic enteritis  
Irritable Bowel Syndrome (IBS)  
Lupus & ALS *Salmonella contamination*  
*Cytokine Storm*  
Botulism Graves' Disease  
Porcine Reproductive Syndrome



# What do all these global health issues have in common?



Drug-resistant pathogens  
**Autoimmune Disorders**  
Sepsis/Toxic Shock  
**Poultry Coccidiosis**  
Antibiotic residues in dairy products  
*e.Coli contamination* Antibiotic-laced meat  
Bovine Mastitis  
Type 1 Diabetes **Arthritis**  
Multiple Sclerosis Necrotic enteritis  
Irritable Bowel Syndrome (IBS)  
Lupus & ALS *Salmonella contamination*  
*Cytokine Storm*  
Botulism Graves' Disease  
Porcine Reproductive Syndrome

They begin and  
end with the  
Immune System




## Human Market Annualized

Antibiotics	\$40.0B	(2020)
Eubiotics	\$37.9B	(2019)
Autoimmune	\$110.0B	(2017)
Antidiabetic	\$48.8B	(2018)

Immune-related and infectious diseases represent a vast range of health issues affecting millions of humans and animals. New applications in pharma, food and nutraceuticals are continually introduced into this growing market

See Addendum for Markets sourcing footnotes







# Billions spent on therapeutics, medicines, additives, ingredients



## Animal Health Market

Vaccines	\$9.2B	(2020)
Phylogenics	\$753.0M	(2020)
Eubiotics	\$3.9B	(2019)

## Companion Animal Market


Drugs, vaccines, additives	\$11.8B (2020)
Supplements	\$637.6M (2019)



See Addendum for Markets sourcing footnotes



Antimicrobial Drugs for Livestock 2018 US - Only






## Poultry Market Annualized

Vaccines	\$2.0B	(2018)
Phytogenics	\$323.0M*	(2020)
Eubiotics	\$1.3B	(2019)

\* Assumes the poultry segment of the overall phytogenics market is approximately 43%


Our global food supply is reliant on antimicrobials, antibiotics and feed chemicals to increase production of animal food products, creating the potential for drug-resistant bugs and the presence of unmetabolized drugs or chemicals in the food at our dinner table

See Addendum for Markets sourcing footnotes





# A two-tiered platform for human and animal immune health



## Immune health touches all aspects of life

### Pharma - Biotech

- Patent-pending immune modulator candidate may create a new class of therapeutics or immune products
- Potential impact in multibillion-dollar global animal products and dairy products market sectors

### Nutrition - Agtech

- Patented, proprietary algal bioproducts aimed at rapidly-growing global demand for plant-based immune & gut health
- Sustainable, non-GMO functional food, feed and beverage ingredients represent expansive, adaptable product platform





# ZIVO Biotech In Vitro Studies

**Biotech**

Biotechnology

Molecules  
Compounds  
Complexes

Immune Cell Membrane

ZIVO is developing product candidates designed to help regulate the healthy response of immune cell receptors to invading pathogens, trauma or metabolic distress


Interior of Immune Cell

Toll-Like Receptor 4 (TLR4)

ZIVO Immune Modulator

Bacteria

Cytokines




# AgTech

Algal Biomass  
Extracts  
Agricultural Technology Dry Mixes

## Immune & Metabolic Health

ZIVO-sponsored *in vitro* and *in vivo* studies and analyses point toward

- A promising new superfood
- Novel topical skin health candidate
- A functional food ingredient
- Supports healthy immune response
- Supports healthy microbiome
- GRAS self-affirmed for immediate sale in the US







## Biotech

Biotechnology

Molecules  
Compounds  
Complexes

Q4 2019 – Q1 2021

### Immune Modulating Molecules

- TLR-4 immune modulator candidate Q4 2019
- Ten (10) patents filed since Q4 2019
- Manufacturing Proof of Concept confirmed Q4 2020

### Poultry Digestive Health

- Seventeen (17) major *in vivo* studies evaluating efficacy and safety, most recently second half 2020
- Histopathology exams of 6,560 intestinal samples
- Licensing deals in discussion for next-gen products that address coccidiosis and feed conversion

### Bovine Mastitis

- Two (2) multianalyte *in vivo* studies of mastitis-inducing pathogens, most recently *staph aureus*
- Zoetis option/collaboration extended to Q3 2021

## AgTech

Agricultural Technology

Algal Biomass  
Extracts  
Dry Mixes

### Product Development Facilities

- Lab opened in Ft. Myers, FL for cultivation optimization and product development, designed specifically for ZIVO algae and cultures

### Production & Cultivation

- Engineering, computer fluid dynamics modeling completed Jan 2021
- License agreement for pilot algae production in Ica, Peru Q2 2020
- Principal engineering and facilities planning completed for Mexico production site Q4 2020

### Product Development & Compliance

- Topical skin product testing started
- Pre-clinical efficacy claims studies planned for ingestible and topical products





ZIVO has also filed national-phase applications in Canada, Mexico, Brazil, EU, Taiwan, China, India, Japan and/or international CTPs for the following:

## US Patents Issued/Allowed

U.S. Patent No. 7,807,622 issued October 5, 2010, "Composition and Use of Phyto-Percolate for Treatment of Disease" Proprietary ZIVO complex algal culture

U. S. Patent No. 8,586,053 issued November 19, 2013, "Composition and Use of Phyto-percolate for Treatment of Disease." Proprietary ZIVO algal culture, with enhancements in application

U.S. Patent No. 8,791,060 issued July 29, 2014, "Composition and Use of Phyto-percolate for Treatment of disease." Same title as earlier patent, with enhancements in application

U.S. Patent No. 9,486,005 issued November 8, 2016, "Agents and Mechanisms for Treating Hypercholesterolemia." Describes potential pharmaceutical application, specifically CETP inhibition

U.S. Patent No. 10,166,270, issued January 1, 2019 "Composition and Method for Affecting Cytokines and NF-KB." Describes potential pharmaceutical application for isolates and derivatives of ZIVO algal culture

U.S. Patent No. 10,232,028, issued March 19, 2019, "Compounds and Methods for Affecting Cytokines." Describes a ZIVO phyto-percolate isolate for affecting cytokines in animals

U.S Patent No. 10,765,732, issued September 8, 2020, "Compounds and Methods for Affecting Cytokines." Same title as earlier patent and describes a ZIVO phyto-percolate isolate for wider applications

U.S. Patent No. 10,842,179, issued November 24, 2020, "Agents and Mechanisms for Treating Hypercholesterolemia." Describes potential pharmaceutical application for a fermented, proprietary ZIVO culture

U.S. Patent No. TBD, allowed March 16, 2021, "Methods of Modulating Immune and Inflammatory Responses Via Administration of an Algal Biomass." Describes the potential nutritional applications of ZIVO algal biomass and extracts to address immune and inflammatory response by enhancing gut health

## Trademarks & Trade Secrets

U.S. Trademarks "ZIVO" 88/288,317; "ZIVO Bioscience" 88/288,453; "Immunoalexin" 88/870,861; "Kalgae" 87/961,009

China Trademarks "ZIVO Bioscience" – China trademark 2019

ZIVO proprietary algal strain has been verified as unique by a third-party and deposited under the World Intellectual Property Organization (WIPO) rules via a certified International Depositary Authority (IDA) under the Budapest Treaty

## Biotech


ZIVO intends to license its proprietary molecules or bioproducts and derive near-term revenues from option and licensing fees, to be followed by long-term royalty streams

#1 - Poultry Digestive Health	#2 - Porcine Immune	#3 - Bovine Mastitis	#4 - Canine Joint Health	#5 - Immune Modulation*
<b>IP Licensing/Partnering Models</b> <ul style="list-style-type: none"> <li>Discovery Stage Licensing, OR</li> <li>Joint Development Agreement (JDA)</li> </ul>	<b>IP Licensing/Partnering Models</b> <ul style="list-style-type: none"> <li>Discovery Stage Licensing, OR</li> <li>Joint Development Agreement (JDA)</li> </ul>	<b>Pharma Discovery Stage Licensing</b> <ul style="list-style-type: none"> <li>Product candidate licensed to pharmaceutical company or drug development partner</li> </ul>	<b>Pharma Discovery Stage Licensing</b> <ul style="list-style-type: none"> <li>Product candidate licensed to pharmaceutical company or drug development partner</li> </ul>	<b>IP Licensing/Partnering Models</b> <ul style="list-style-type: none"> <li>Discovery Stage Licensing, OR</li> <li>Joint Development Agreement (JDA)</li> </ul>
<b>Expected Revenue Stream</b> <ul style="list-style-type: none"> <li>Option &amp; License payments, then royalties over 17+ years, OR</li> <li>JDA revenue share over 17+ years</li> </ul>	<b>Expected Revenue Stream</b> <ul style="list-style-type: none"> <li>Option &amp; License payments, then royalties 17+ years, OR</li> <li>JDA revenue share over 17+ years</li> </ul>	<b>Expected Revenue Stream</b> <ul style="list-style-type: none"> <li>Option &amp; License payments, then royalties over 17+ years</li> </ul>	<b>Expected Revenue Stream</b> <ul style="list-style-type: none"> <li>Option &amp; License payments, then royalties over 17+ years</li> </ul>	<b>Expected Revenue Stream</b> <ul style="list-style-type: none"> <li>Option &amp; License payments, then royalties over 17+ years, OR</li> <li>JDA revenue share over 17+ years</li> </ul>

\*Phase 3 required for human applications

Represents a potential opportunity for significant value inflection

### Typical Drug Development Timeline




\*Investigational New Drug

## AgTech

ZIVO plans a global algae production network and derive near-term revenues from distribution fees and licensing fees, followed by long-term distribution and joint-venture revenues

Skin Health/Anti-Aging Products	Aquaculture	Joint/Exertion Recovery	Organic Poultry Feed Ing.	Food/Beverage Ingredient
<b>Joint Venture Model</b> <ul style="list-style-type: none"> <li>50/50 gross margin split with JV partners for exclusive verticals</li> </ul> <b>Fees, Advances and Revenues</b> <ul style="list-style-type: none"> <li>Licensed regional distribution fees</li> <li>Revenues from ingredient and formulated product sales</li> </ul>	<b>Licensed Distribution Model</b> <ul style="list-style-type: none"> <li>Distributor model for US/EU</li> </ul> <b>Fees, Advances and Revenues</b> <ul style="list-style-type: none"> <li>No fees, advances anticipated</li> <li>Revenues from ingredient and formulated product sales</li> </ul>	<b>Licensed Distribution Model</b> <ul style="list-style-type: none"> <li>Distributor model for US/EU</li> </ul> <b>Fees, Advances and Revenues</b> <ul style="list-style-type: none"> <li>Licensed regional distribution fees</li> <li>Revenues from ingredient and formulated product sales</li> </ul>	<b>Joint Marketing Model</b> <ul style="list-style-type: none"> <li>50/50 gross margin split with exclusive marketing partner</li> </ul> <b>Fees, Advances and Revenues</b> <ul style="list-style-type: none"> <li>No fees, advances anticipated</li> <li>Revenues from ingredient sales</li> </ul>	<b>Licensed Distribution Model</b> <ul style="list-style-type: none"> <li>Distributor model for US/EU</li> </ul> <b>Fees, Advances and Revenues</b> <ul style="list-style-type: none"> <li>Licensed regional distribution fees</li> <li>Revenues from ingredient and pre-blended ingredient sales</li> </ul>

Revenues anticipated to commence shortly after funding





# Leadership Team



**Andrew A. Dahl - President and CEO**

Over 30 years experience in business case development, marketing planning and business development. Mr. Dahl brings Fortune 500 rigor and diligence to early-stage life science companies, setting priorities, shaping business models and facilitating resources to drive toward the Company's overall business objectives.



**Harlan L. Miller III, PhD – VP Technology and Global Supply**

Dr. Miller is a recognized expert in algal production systems, previously as Sr. Technology Director - Algenol Biotech, LLC. He manages international farm conversions SuperFarm engineering and global tech support, and also directs cultivation science and product development at Ft. Myers research facility.



**Keith R. Marchiando – CFO**

25 years of functional experience and technical knowledge in corporate finance, planning, and accounting for manufacturing and technology firms. Mr. Marchiando holds broad responsibilities for all finance functions, HR, legal and IT matters. Mr. Marchiando is also corporate secretary and reporting/compliance officer.



**Amy E Steffek, PhD - Director R&D**

Over 20 years in life science startups ranging across clinical/analytic research, study coordination and regulatory compliance. Dr. Steffek manages multiple research studies, analyses and reporting of research findings pertaining to the Company's proprietary, naturally derived compounds and bioactive molecules



**William P. Pfund, MS - VP R&D**

Wide-ranging career in Big Pharma, life science startups and contract research orgs. Responsible for all R&D strategies aimed at developing and validating novel therapeutics and product candidates from ZIVO's proprietary bioproducts, leveraging specific expertise in analytical, *in vitro*, and *in vivo* sciences.




**Casey W. Fowler, MS - VP Operations**

With a decade of managing IP assets, Mr. Fowler manages all IP strategy and assets, as well as operational functions for design and implementation of business strategies, plans and procedures. Additionally, Mr. Fowler leads several specific strategic imperatives at the direction of the executive team.



## Biotech

ZIVO intends to license its proprietary molecules or bioproducts and look for opportunities to fully monetize its intellectual property portfolio across multiple applications



### #1 - Poultry Digestive Health

#### Therapeutic/Immune Product

- Bioproduct designed to be introduced into poultry feed or drinking water

### #2 - Porcine Immune

#### Therapeutic/Immune Product

- Bioproduct intended for introduction into swine feed or drinking water

### #3 - Bovine Mastitis

#### Therapeutic/Immune Product

- Liquid product intended primarily for intramammary infusion

### #4 - Canine Joint Health

#### Therapeutic/Medicinal Product

- Bioproduct in capsule, caplet or bolus form intended for oral administration

### #5 - Immune Modulation

#### Therapeutic/Medicinal Product

- Bioproduct in capsule, caplet or bolus form intended for oral administration

ZIVO to approach markets sequentially, building on the success and cash flow of each previously launched application to address the next vertical or application



## AgTech

ZIVO plans a global algae production network and derive revenues from selling biomass and joint ventures that market formulated products featuring ZIVO natural biomass products

### #1 Skin Health/Anti-Aging

#### Ingredient Sales & Formulations

- Nutricosmetics, cosmeceuticals, nutraceuticals, topical skin product intended use

### #2 Aquaculture

#### Feed Ingredient

- Functional ingredient for farmed shrimp and fish fry
- Dried algal powder or frozen paste form

### #3 Joint/Exertion Recovery

#### Formulated Product

- ZIVO algae mixed with other ingredients for oral consumption
- Capsule, bolus, caplet or powder form

### #4 Food/Beverage Ingredient

#### Licensed Ingredient

- Dried algal biomass for use in various food & beverage applications

### #5 Organic Poultry Feed

#### Probiotic Ingredient Comp

- Dried algal biomass mixed into dry poultry feed

ZIVO plans to generate near-term revenue from sales of outsourced algal biomass through licensed contract growers in LATAM, Mexico and US





# Where ZIVO is Headed – Goals for 2021 and Beyond

## Biotech

Biotechnology

Molecules  
Compounds  
Complexes

### Poultry Digestive Health

- Prospective licensing or joint development deal
- Continue refinement of poultry product candidates
- Productize, commercialize successful market entry

### Immune Modulating Product

- Commercial scale ramp-up of bioactive molecules
- Begin testing in swine and canine models

### Intellectual Property Portfolio

- Targeting 50+ patents pending across the globe
- Zoetis option/collaboration extended to Q3 2021

Patents filed. Tested. Ready to license.

An opportunity for major value inflection.

## AgTech

Agricultural Technology

Algal Biomass  
Extracts  
Dry Mixes

### Strategic Partnerships & Regional Distributors

- Establish regional distributorships in US, EU, ME, SEA,
- Form JVs to create new marketing channels, products

### Production & Global Supply Chain

- Recruit agribusinesses globally as licensed growers
- Establish global supply chain with QC compliance
- Expand ZIVO algae production in LATAM

### Product Development & Compliance

- Planned launch of functional food ingredient in US, EU
- Topical skin health ingredient and formulated product launch in US, UK pending regulatory approvals

Patents filed. Tested. Market-ready.

An opportunity for immediate revenue.




Thank You!

# Sourcing Footnote Addendum

Page in Deck	Item	Source / Notes
9	Human - Antibiotics - \$40B	"The global antibiotics market size was valued at USD 40.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.5% from 2021 to 2028." <a href="https://www.grandviewresearch.com/industry-analysis/antibiotic-market">https://www.grandviewresearch.com/industry-analysis/antibiotic-market</a>
9	Human - Eubiotics - \$37.9B	"The market size stood at USD 37.93 billion in 2019." <a href="https://www.globenewswire.com/news-release/2021/02/12/2174760/0/en/Digestive-Health-Market-to-Reach-USD-71-95-billion-and-Exhibit-a-CAGR-of-7-9-by-2027-Rising-Awareness-about-Gut-Health-to-Intensify-Market-states-Fortune-Business-Insights.html">https://www.globenewswire.com/news-release/2021/02/12/2174760/0/en/Digestive-Health-Market-to-Reach-USD-71-95-billion-and-Exhibit-a-CAGR-of-7-9-by-2027-Rising-Awareness-about-Gut-Health-to-Intensify-Market-states-Fortune-Business-Insights.html</a>
9	Human - Autoimmune - \$110.0B	"Global Autoimmune Disease Therapeutics Market accounted for \$109.83 billion in 2017 and is estimated to garner \$153.32 billion by 2025, registering a CAGR of 4.2% from 2018 to 2025." Allied Market Research, Report 2019: <a href="#">Global Autoimmune Disease Therapeutics Market to Garner \$153.32 Billion by 2025 at 4.2% CAGR, Says Allied Market Research</a> .
9	Human - Antidiabetic - \$48.7	"The global diabetes drugs market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled "Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026," the market was valued at US\$ 48,753.1 Mn in 2018." <a href="https://www.globenewswire.com/news-release/2020/08/19/2080514/0/en/Diabetes-Drugs-Market-to-Expand-at-6-1-CAGR-to-Reach-US-78-261-7-Mn-by-2026-Global-Market-Size-Share-Analysis-Forecast-2019-2026.html">https://www.globenewswire.com/news-release/2020/08/19/2080514/0/en/Diabetes-Drugs-Market-to-Expand-at-6-1-CAGR-to-Reach-US-78-261-7-Mn-by-2026-Global-Market-Size-Share-Analysis-Forecast-2019-2026.html</a>
10	Animal - Vaccines - \$9.	"The global animal vaccines market size was valued at USD 9.2 billion in 2020." <a href="https://www.grandviewresearch.com/industry-analysis/veterinary-animal-vaccines-market">https://www.grandviewresearch.com/industry-analysis/veterinary-animal-vaccines-market</a>
10	Animal - Phytogenics - \$753M	"The global phytogenic feed additives market size is estimated to account for USD 753 million in 2020." <a href="https://www.marketsandmarkets.com/Market-Reports/feed-phytogenic-market-162036047.html">https://www.marketsandmarkets.com/Market-Reports/feed-phytogenic-market-162036047.html</a>
10	Animal - Eubiotics - \$3.9B	"Global Eubiotics Market size exceeded USD 3.9 Billion, globally in 2019 and is estimated to grow at over 8.5% CAGR between 2020 and 2026." <a href="https://www.gminsights.com/industry-analysis/eubiotics-market">https://www.gminsights.com/industry-analysis/eubiotics-market</a>
10	Companion Animal – Drugs, vaccines and additives - \$11.8B	"Companion Animal Drugs Market size was valued at around USD 11.83 billion in 2020." "Companion animal drugs include several drugs, vaccines and medicated feed additives" <a href="https://www.gminsights.com/industry-analysis/companion-animal-drugs-market?utm_source=globenewswire.com&amp;utm_medium=referral&amp;utm_campaign=Paid_globenewswire">https://www.gminsights.com/industry-analysis/companion-animal-drugs-market?utm_source=globenewswire.com&amp;utm_medium=referral&amp;utm_campaign=Paid_globenewswire</a>
10	Companion Animal – Supplements - \$637.6M	"According to the research study, the global Pet Supplements Market was estimated at USD 637.6 million in 2019 and is expected to reach USD 1023.8 million by 2026." <a href="https://www.globenewswire.com/news-release/2020/11/19/2130018/0/en/Global-Pet-Supplements-Market-Share-Will-Grow-to-USD-1023-8-Million-by-2026-Facts-Factors.html">https://www.globenewswire.com/news-release/2020/11/19/2130018/0/en/Global-Pet-Supplements-Market-Share-Will-Grow-to-USD-1023-8-Million-by-2026-Facts-Factors.html</a>
11	Poultry - Vaccines - \$2.0B	"The global poultry vaccines market size was estimated at USD 2.0 billion in 2018 and is expected to exhibit a CAGR of 6.2% during the forecast period." <a href="https://www.grandviewresearch.com/industry-analysis/poultry-vaccines-market">https://www.grandviewresearch.com/industry-analysis/poultry-vaccines-market</a>
11	Poultry - Phytogenics - \$323.0M	"The global phytogenic feed additives market size was USD 754 Million in 2020 and is expected to register a CAGR of 7.7% during the forecast period." <a href="https://www.reportsanddata.com/report-detail/phytogenic-feed-additives-market">https://www.reportsanddata.com/report-detail/phytogenic-feed-additives-market</a> .

# Sourcing Footnote Addendum

Page in Deck	Item	Source / Notes
11	Poultry Phylogenics - \$323.0M	<p>Poultry segment of overall phylogenics market is 43%</p> <div><p>Feed Phylogenics Market</p><p>43%</p><p>Poultry is the largest consumer and accounts for 43% share of Feed Phylogenics Market.</p><p>Mordor Intelligence</p></div> <p><a href="https://mordorintelligence.com">mordorintelligence.com</a></p> <h3>Feed Phytogetic Market   Share   Analysis</h3> <p>The global #feed #phytogetic market is poised to grow \$675 million by 2020 growing at the CAGR of 3.5% during the forecast period 2015-2020. Essential Oils feed market is the major segment in European...</p> <p><b>More</b></p> <p><b>MORDOR INTELLIGENCE</b> 78 followers</p> <p><b>Follow</b></p> <p><b>Photos</b> Comments</p> <p>Tried this Pin? Add a photo to show how it went</p> <p><b>Add photo</b></p> <p>MORDOR INTELLIGENCE saved to Animal Feed</p>